Expect near-term stock price pressure from the dilutive offering and the below-market warrant exercise price ($0.75). The registration rights will likely lead to an S-1 filing within 30 days, potentially accelerating selling by purchasers. Monitor for any Q2 2026 earnings release or business update that could provide context on the cash burn rate and timeline to next financing.
Price Chart
Executive Summary
Aspira Women's Health raised approximately $1.485 million in a private placement, issuing 3.3M shares of common stock at $0.45 per share and 4.455M warrants exercisable at $0.75 per share (3-year term). The offering is dilutive (7.8 million total potential shares vs. a likely small existing float) and priced at a significant discount to likely market price, indicating urgent capital needs for working capital at a company already trading on the OTCQX.
Key Financial Metrics
Key Facts
- Gross proceeds of $1.485 million from sale of 3.3M shares and warrants to purchase 4.455M shares
- Purchase price of $0.45 per unit (share + warrant), with warrant exercise price of $0.75
- Warrants are immediately exercisable, with a 3-year term and 135% coverage ratio
- Proceeds to be used for working capital and general corporate purposes
- Shares and warrants were issued in reliance on Section 4(a)(2)/Reg D private placement exemption
- Registration rights granted for resale of shares and warrant shares
- Company trades on OTCQX with no recent financial performance data in filing
- 20 purchasers participated, including individuals and trusts, suggesting no institutional anchor
- One-time economic parity adjustment (anti-dilution) provision tied to next round of financing
- No prior cross-filings indicate distress, but the capital raise itself signals cash constraints
Financial Impact
Offering size of $1.485 million gross is material for a small-cap diagnostics company; 3.3M shares plus up to 4.455M warrant shares could represent substantial dilution relative to pre-offering float. No market price data provided to calculate exact dilution %.
Risk Factors
- Dilution from up to 7.8M total potential shares (3.3M shares + 4.455M warrant shares) relative to current float could exceed 50%
- Warrant exercise price of $0.75 is above issuance price but may create overhang if stock trades near that level
- OTCQX listing limits institutional liquidity and may amplify price moves on selling
- Working capital use suggests ongoing cash burn without disclosed revenue trajectory
- No analyst consensus or earnings data provided to assess valuation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000926617-26-000042 |
| Document: awhl-20260529xex4d1.htm | 0000926617-26-000042 |
| Document: awhl-20260529x8k.htm | 0000926617-26-000042 |
| Document: 0000926617-26-000042-index-headers.html | 0000926617-26-000042 |
| Document: 0000926617-26-000042-index.html | 0000926617-26-000042 |
| Document: 0000926617-26-000042.txt | 0000926617-26-000042 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 22, 2026 18w ago | 8-K | $0.4600 $0.2900 | ▲ +36.96% | ▲ +39.17% | $0.1388 (+69.83%) |
Jun 9, 2026 20w ago | 8-K | $0.4300 $0.2786 | ▲ +35.21% | ▲ +39.29% | $0.1388 (+67.72%) |
May 29, 2026 21w ago | Insider Cluster | $0.5400 $0.2700 | ▼ −50.00% | ▼ −51.23% | $0.1388 (−74.30%) |
May 26, 2026 22w ago | 8-K | $0.4600 $0.3100 | ▼ −32.61% | ▼ −35.33% | $0.1388 (−69.83%) |
Apr 30, 2026 25w ago | 8-K | $0.3900 $0.3509 | ▼ −10.03% | ▼ −13.09% | $0.1388 (−64.41%) |
Apr 28, 2026 25w ago | DEFA14A | $0.4000 $0.4000 | · 0.00% | ▼ −4.11% | $0.1388 (−65.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers